Yubo International Biotech (Yubo International Biotech) Cash-to-Debt : 0.20 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Yubo International Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.20.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Yubo International Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Yubo International Biotech's Cash-to-Debt or its related term are showing as below:

YBGJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 4.39
Current: 0.2

During the past 4 years, Yubo International Biotech's highest Cash to Debt Ratio was 4.39. The lowest was 0.00. And the median was 0.03.

YBGJ's Cash-to-Debt is ranked worse than
86.05% of 839 companies
in the Medical Devices & Instruments industry
Industry Median: 1.98 vs YBGJ: 0.20

Yubo International Biotech Cash-to-Debt Historical Data

The historical data trend for Yubo International Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Yubo International Biotech Cash-to-Debt Chart

Yubo International Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

4.39

0.01

0.02

Yubo International Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												0.05	0.01	0.01	0.02	0.20

Competitive Comparison of Yubo International Biotech's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Cash-to-Debt falls into.

Yubo International Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Yubo International Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.006	/	(0.276	+	0.116)
	=	0.02

Yubo International Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.057	/	(0.2	+	0.091)
	=	0.20

Yubo International Biotech (OTCPK:YBGJ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Yubo International Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Yubo International Biotech (Yubo International Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034

Website

http://www.yubogroup.com

Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.

Executives

Lina Liu	10 percent owner, officer: CFO, Treasurer and Secretary	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui	director	MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun	director, officer: President and CEO	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang	director	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth	director	C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc	10 percent owner	8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica	officer: Treasurer and Secretary	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff	director, officer: Chairman, President, CSO	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman	director	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler	director	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines